---
title: "Alphatec Holdings, Inc. Stock 12‑Month Price Target Cut to $14.68, Implies 29% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303756241.md"
description: "Alphatec Holdings, Inc. stock's average 12-month price target has been cut to $14.68 (reported as $14.96 in body) by 14 analysts, implying a ~32% upside from the Oct. 29 close. The range is $11-$24. Despite the cut, the consensus rating remains 'Buy' with all 14 analysts maintaining this stance."
datetime: "2026-10-30T13:20:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303756241.md)
  - [en](https://longbridge.com/en/news/303756241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303756241.md)
generator: "portal-rs"
---

# Alphatec Holdings, Inc. Stock 12‑Month Price Target Cut to $14.68, Implies 29% Upside

-   According to estimates from 14 analysts, Alphatec Holdings, Inc. stock's average price target has fallen from $15.79 to $14.96, with forecasts ranging from $11 to $24 per share
-   Based on the Oct. 29 closing price, the updated target implies approximately 32% potential upside
-   Consensus rating remains at “Buy” across 14 covering analysts, with 14 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Alphatec Holdings, Inc. on the , and track all previous and future analyst recommendations for Alphatec Holdings, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ATEC.US](https://longbridge.com/en/quote/ATEC.US.md)

## Related News & Research

- [Did Alphatec's Fall Catch You Out? What Investors Missed](https://longbridge.com/en/news/303089224.md)
- [JP Morgan maintains Alphatec Holdings at Overweight, lowers price target to $15 from $16](https://longbridge.com/en/news/303811177.md)
- [ATEC Q3 2026 Earnings: Biologics Weakness Limits Revenue Growth](https://longbridge.com/en/news/303624186.md)
- [ATEC: Surgical demand strengthened, but biologics attachment constrained Q3 revenue](https://longbridge.com/en/news/303621217.md)
- [Nextpower Inc (NXT) Gets a Buy from Wells Fargo](https://longbridge.com/en/news/303840692.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**